Share on LinkedInShare on LinkedIn

ARTICLE · 11 APRIL 2012

ECJ Clarifies Scope Of Supplementary Protection Certificate

Van Bael & Bellis
Van Bael & Bellis
Contributor
Van Bael & Bellis

Van Bael & Bellis

Van Bael & Bellis is a leading independent law firm headquartered in Brussels with offices in...

View firm profile
Explore more from Van Bael & Bellis

On 9 February 2012, the Court of Justice of the European Union (the "ECJ") answered a preliminary question referred to it by the High Court of Justice of England and Wales (the "Referring Court") in Novartis AG ("Novartis") v. Actavis UK Ltd.

European UnionIntellectual Property

On 9 February 2012, the Court of Justice of the European Union (the "ECJ") answered a preliminary question referred to it by the High Court of Justice of England and Wales (the "Referring Court") in Novartis AG ("Novartis") v. Actavis UK Ltd. ("Actavis") (Case C-442/11). The ECJ judgment offers guidance on the scope of supplementary protection certificates ("SPCs").

Novartis is a pharmaceutical company which obtained a patent for valsartan, an active ingredient that is mainly administered for the treatment of high blood pressure. Novartis markets Diovan®, a medicinal product with valsartan as its sole active ingredient, and Co-Diovan®, a medicinal product based on valsartan combined with the active ingredient hydrochlorothiazide. The patent for valsartan expired on 12 February 2011. However, Novartis was granted an SPC for valsartan on the basis of the patent for valsartan and the marketing authorisation obtained for Diovan®.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from